This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ridgway, E. C. Articles by McLachlan, S. M. Search for Related Content PubMed PubMed Citation Articles by Ridgway, E. C. Articles by McLachlan, S. M. Related Collections Autoimmunity Endocrine Oncology Thyroid

Update in Thyroidology

Division of Endocrinology, Metabolism, and Diabetes (E.C.R.), Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado 80045; Division of Endocrinology, Diabetes, and Metabolism (Y.T.), Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio 45221; and Department of Medicine (S.M.M.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California 90025

Address all correspondence and requests for reprints to: E. Chester Ridgway, M.D., MACP, University of Colorado Health Science Center, MS 8106, P.O. Box 6511, Aurora, Colorado 80045. E-mail: e.chester.ridgway{at}uchsc.edu.

The human and mouse genome databases have provided powerful tools to probe many unanswered questions in thyroidology. Mechanistic knowledge regarding thyroid development, thyroid gland regulation by hypothalamic-pituitary function, thyroid hormone transport and action, thyroid autoimmunity and genetics, and thyroid oncogenesis have expanded enormously using molecular genetics. This basic information is providing the foundation for new clinical approaches to the diagnosis and therapy of thyroid disorders. For example, old dogma regarding the transport of thyroid hormones into cells being mediated by passive diffusion is being discarded as knowledge of new small molecule transporters has been discovered and related to human disease. The genetic basis for autoimmune thyroid disease is being unraveled by discovery of genetic variations associated with risk for autoimmune disease and important molecules in the disorder’s pathogenesis. The translation of basic molecular genetic knowledge into clinical care is no better illustrated than in thyroid cancer, in which genetic mutations in molecules of the MAPK pathway have been shown to account for more than 70% of papillary thyroid cancers. Furthermore, certain mutations may predict clinical outcomes, such as cancer recurrence. The new molecular understanding of thyroid cancer causation is now opening a new therapeutic frontier as drugs are developed that modulate the MAPK pathway.